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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of sound therapy (using amplification devices and/or sound generators) for tinnitus in adults.
B A C K G R O U N D
This is a new protocol for an update of two Cochrane Reviews on
sound therapy (masking) and on amplification with hearing aids
for tinnitus that were first published in the Cochrane Library in
Issue 12, 2010 and updated in 2012 (Hobson 2012) and in Issue
1, 2014 (Hoare 2014), respectively. The following paragraphs and
Description of the condition are based on the latter Cochrane
Review ’Amplification with hearing aids for patients with tinnitus
and co-existing hearing loss’ and are reproduced with permission
(Hoare 2014).
Tinnitus is defined as the perception of sound in the absence of
an external source (Jastreboff 2004). It is typically described by
those who experience it as a ringing, hissing, buzzing or whoosh-
ing sound and is thought to result from abnormal neural activity
at some point or points in the auditory pathway, which is erro-
neously interpreted by the brain as sound. Tinnitus can be either
objective or subjective. Objective tinnitus refers to the perception
of sound that can be also heard by the examiner and is usually due
to turbulent blood flow or muscular contraction (Roberts 2010).
Most commonly, however, tinnitus is subjective; the sound is only
heard by the person experiencing it and no source of the sound is
identified (Jastreboff 1988).
Tinnitus affects between 5% and 43% of the general population
and prevalence increases with age (McCormack 2016). It can be
experienced acutely, recovering spontaneously within minutes to
weeks, but is considered chronic and unlikely to resolve sponta-
neously when experienced for more than three months (Gallus
2015; Hall 2011).
For many people tinnitus is persistent and troublesome, and has
disabling effects such as insomnia, difficulty concentrating, dif-
ficulties in communication and social interaction, and negative
emotional responses such as anxiety and depression (Hall 2018).
In approximately 90% of cases, chronic tinnitus is co-morbid with
some degree of measurable hearing loss, which may confound
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these disabling effects (Fowler 1944; Sanchez 2002). Nevertheless,
the association between hearing loss and tinnitus is not simple or
straightforward; not all people with hearing loss experience tin-
nitus, and conversely some people with clinically normal hearing
have tinnitus (Baguley 2013). It has been reported that 40% of
patients are unable to identify what health condition is associated
with their tinnitus onset, i.e. the tinnitus is idiopathic (Henry
2005).
An important implication in clinical research is that outcomemea-
sures need to distinguish benefits specific to improved hearing
from those specific to improvement in the psychological aspects
of tinnitus.
Description of the condition
Diagnosis and clinical management of tinnitus
There is no standard procedure for the diagnosis ormanagement of
tinnitus. Practice guidelines and the approaches described in stud-
ies of usual clinical practice typically reflect differences between
the clinical specialisms of the authors or differences in the clinical
specialisms charged with meeting tinnitus patients’ needs (medi-
cal, audiology/hearing therapy, clinical psychology, psychiatry), or
the available resources of a particular country or region (access to
clinicians or devices, for example) (Biesinger 2010; Cima 2012;
Department of Health 2009; Hall 2011; Henry 2008; Hoare
2011). Common across all these documents, however, is the use or
recommendation of written questionnaires to assess tinnitus and
its impact on patients and their families by measuring tinnitus
symptom severity (e.g. impact of tinnitus on quality of life, activ-
ities of daily living or sleep), and a judgement about patients who
are experiencing a degree of psychological distress (depression or
anxiety). Assessment of the perceptual characteristics of tinnitus
(pitch, loudness, minimummasking level) and residual inhibition
are also recommended (Cima 2018). Although these measures do
not correlate well with tinnitus symptom severity (Hiller 2006),
they can prove useful in patient counselling (Henry 2004), as a
baseline before start of treatment (El Refaie 2004), or by demon-
strating stability of the tinnitus percept over time (Department of
Health 2009).
Clinical management strategies include education and advice, re-
laxation therapy, tinnitus retraining therapy (TRT), cognitive be-
havioural therapy (CBT), sound enrichment using ear-level sound
generators or hearing aids, and drug therapies to manage co-mor-
bid symptoms such as insomnia, anxiety or depression (for exam-
ple, Department of Health 2009; Tunkel 2014). As yet, no drug
has been approved for tinnitus by a regulatory body (e.g. the Eu-
ropeanMedicines Agency or US Food and Drug Administration).
Pathophysiology
Most people with chronic tinnitus have some degree of measur-
able hearing loss (Ratnayake 2009), and the prevalence of tinnitus
increases with greater hearing loss (Han 2009; Martines 2010).
The varying theories of tinnitus generation involve changes in ei-
ther function or activity of the peripheral (cochlea and auditory
nerve) or central auditory nervous systems (Henry 2005). Theo-
ries involving the peripheral systems include the discordant dam-
age theory, which predicts that the loss of outer hair cell function,
where inner hair cell function is left intact, leads to a release from
inhibition of inner hair cells and aberrant activity (typically hy-
peractivity) in the auditory nerve (Jastreboff 1990). Such aberrant
auditory nerve activity can also have a biochemical basis, resulting
from excitotoxicity or stress-induced enhancement of inner hair
cell glutamate release with upregulation of N-methyl-D-aspartate
(NMDA) receptors (Guitton 2003; Sahley 2001).
In the central auditory system, structures implicated as possible
sites of tinnitus generation include the dorsal cochlear nucleus
(Middleton 2011; Pilati 2012), the inferior colliculus (Dong 2010;
Mulders 2010), and the auditory and non-auditory cortex (dis-
cussed further below). There is a strong rationale that tinnitus is a
direct consequence of maladaptive neuroplastic responses to hear-
ing loss (Moller 2000;Muhlnickel 1998). This process is triggered
by sensory deafferentation and a release from lateral inhibition in
the central auditory system allowing irregular spontaneous hyper-
activity within the central neuronal networks involved in sound
processing (Eggermont 2004; Rauschecker 1999; Seki 2003). As
a consequence of this hyperactivity, a further physiological change
noted in tinnitus patients is increased spontaneous synchronous
activity occurring at the subcortical and cortical level, measurable
using electroencephalography (EEG) ormagnetoencephalography
(MEG) (Dietrich 2001; Tass 2012; Weisz 2005). Another physi-
ological change thought to be involved in tinnitus generation is a
process of functional reorganisation, which amounts to a change
in the response properties of neurons within the primary auditory
cortex to external sounds. This effect is well demonstrated physio-
logically in animal models of hearing loss (Engineer 2011; Norena
2005). Evidence in humans, however, is limited to behavioural
evidence of cortical reorganisation after hearing loss, demonstrat-
ing improved frequency discrimination ability at the audiomet-
ric edge (Kluk 2006; McDermott 1998; Moore 2009; Thai-Van
2002; Thai-Van 2003), although Buss 1998 did not find this ef-
fect. For comprehensive reviews of these physiological models, see
Adjamian 2009 and Norena 2011.
It is also proposed that spontaneous hyperactivity could cause an
increase in sensitivity or ’gain’ at the level of the cortex, whereby
neural sensitivity adapts to the reduced sensory inputs, in effect
stabilising mean firing and neural coding efficiency (Norena 2011;
Schaette 2006; Schaette 2011). Such adaptive changes would be
achieved at the cost of amplifying ’neural noise’ due to the overall
increase in sensitivity, ultimately resulting in the generation of
tinnitus.
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Increasingly, non-auditory areas of the brain, particularly areas as-
sociated with emotional processing, are also implicated in bother-
some tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste 2012
describes tinnitus as “an emergent property of multiple parallel
dynamically changing and partially overlapping sub-networks”,
implicating the involvement of many structures of the brain more
associated withmemory and emotional processing in tinnitus gen-
eration. However, identification of the structural components of
individual neural networks responsible for either tinnitus gener-
ation or tinnitus intrusiveness, which are independent of those
for hearing loss, remains open to future research (Melcher 2013).
One further complication in understanding the pathophysiology
of tinnitus is that not all people with hearing loss have tinnitus
and not all people with tinnitus have a clinically significant and
measurable hearing loss. Other variables, such as the profile of a
person’s hearing loss, may account for differences in their tinnitus
report. For example, Konig 2006 found that the maximum slope
within audiograms was higher in people with tinnitus than in peo-
ple with hearing loss who do not have tinnitus, despite the ’non-
tinnitus’ group having the greater mean hearing loss. This sug-
gests that a contrast in sensory inputs between regions of normal
and elevated threshold may be more likely to result in tinnitus.
However, this finding is not consistent across the literature (Sereda
2011; Sereda 2015a).
Description of the intervention
Amplification devices (hearing aids)
The following description of hearing aids is taken from the
Cochrane Review ’Amplification with hearing aids for patients
with tinnitus and co-existing hearing loss’ and reproduced with
permission Hoare 2014.
The standard function of a hearing aid is to amplify and modulate
sound, primarily for the purpose of making sound more accessible
and aiding communication. Using hearing aids in tinnitus man-
agement has been proposed as a useful strategy since the 1940s
(Saltzman 1947), although benefit reportedly varies and there is no
clear consensus onwhen a personwould or would not benefit from
amplification (Henry 2005; Hoare 2012). Beck 2011 proposes
that hearing aid fittings for people with very mild up to moderate
sensorineural hearing loss (who might not ordinarily look for or
be prescribed a hearing aid) can lead to significant improvements
in tinnitus. Currently, hearing aids, supplemented with education
and advice, form a common intervention for someone who has
tinnitus and an aidable hearing loss (Hoare 2012; Sereda 2015).
This combination of hearing aid provision with education and
advice might be considered a complex intervention with interde-
pendent components (Shepperd 2009).
There are many options for hearing aid fitting that complicate
their use in tinnitus. For example, Del Bo 2007 suggests that the
best clinical result for someone with tinnitus requires binaural am-
plification. Trotter 2008, however, in describing a 25-year expe-
rience of hearing aids in tinnitus therapy found no difference in
tinnitus improvement between unilaterally and bilaterally aided
patients.
For other aspects of hearing aid fitting there appears greater con-
sensus, such as the value of using open-fitting aids (if acoustically
suitable), which allow natural environmental sound to enter the
ear, as well as amplifying those sounds, thus improving perceived
sound quality (Del Bo 2007; Forti 2010).
The bandwidth amplified by the hearing aid may also be impor-
tant to its effect on tinnitus. In a study byMoffat 2009 the tinnitus
percept was not at all affected in a group receiving high-bandwidth
amplification, which had less gain at frequencies below 1 kHz and
more gain at frequencies above 1 kHz than conventional ampli-
fication. In a group receiving conventional amplification, how-
ever, there was a significant reduction of the contribution of all
low-frequency components of the measured tinnitus spectrum to
matched tinnitus. This suggests an interaction between the per-
ceptual characteristics of tinnitus and the pattern of sensory inputs
in this group.
Finally, hearing aid prescription might also be combined with
other forms of therapy such as formal counselling, albeit with
mixed evidence for the efficacy of such combinations of therapies
(Hiller 2005; Searchfield 2010).
Sound generator devices
Sound generators are ear-level devices that produce sounds for
therapeutic use.
Sound generator devices were introduced in 1976, on the prin-
ciple of distraction, turning complete masking of tinnitus with
white noise into a clinical management technique (Vernon 1976).
The purpose of the ’masking’ method was described by Vernon
as making the tinnitus inaudible with a more acceptable sound
(Vernon 1976; Vernon 1977). With the introduction of combina-
tion hearing aids partial masking became an acceptable outcome
of the sound therapy. Partial masking provided only partial reduc-
tion in tinnitus, meaning that the tinnitus could still be heard but
in a suppressed form (Vernon 1988).
Current views on sound generators acknowledge that masking is
only one of the goals of sound therapy, alongside achieving tinnitus
relief (i.e. reduction in tinnitus annoyance) regardless of themech-
anism by which it is achieved (complete masking, partial masking
or not masking the tinnitus; Henry 2008a). Other philosophies
include the use of noise as a form of sound enrichment, counter-
acting the effects of sensory deprivation (Jastreboff 1993).
Recommendations regarding choice of sounds or level of sound
that should be used vary across the literature and often strongly
depend on the management programme followed. For example,
tinnitus masking (TM) permits the use of any sound that provides
maximum masking benefit (Henry 2002). The choice of sound,
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therefore, is based on a combination of effectiveness and accept-
ability for the patient. On the other hand, tinnitus retraining ther-
apy (TRT) recommends the use of broadband noise to be adjusted
to a ’mixing’ or ’blending’ point (Jastreboff 2007; Korres 2010;
McFerran 2009), or below that level (Jastreboff 2006), to allow
for habituation.
Many studies describe sound therapy in the context of a larger
management programme, combining multiple approaches to
manage tinnitus, where the counselling component plays a major
role (e.g. Progressive Tinnitus Management, TRT, Neuromonics).
It is therefore often difficult or even impossible to draw conclu-
sions specific to the sound therapy component of the programme.
It is possible that other components, rather than the devices, might
have played a role in the observed improvements in tinnitus dis-
tress or handicap.
Combination hearing aids
Combination hearing aids combine amplification and sound gen-
eration options within one device, and new generations of such
devices offer the same quality of amplification as ’standard’ hearing
aids (Henry 2004a; Sereda 2017; Tutaj 2018).
How the intervention might work
Hearing aids may be beneficial for people with tinnitus in a num-
ber of ways. The amplification of external sounds may reverse or
reduce the drive responsible for ’pathological’ changes in the cen-
tral auditory system associated with hearing loss, such as increased
gain or auditory cortex reorganisation, possibly by strengthen-
ing lateral inhibitory connections. Increased neuronal activity that
results from amplified sounds may reduce the contrast between
tinnitus activity and background activity thus reducing the audi-
bility and awareness of tinnitus. Alternatively, amplification may
simply refocus attention on alternative auditory stimuli that are
incompatible and unrelated to the tinnitus sound. As the main
function of hearing aids is to improve communication, for many
people this inherently reduces stress and anxiety (Carmen 2002;
Surr 1985), and so may indirectly affect improvements in tinnitus
report. Finally, it is unquestioned that there is the potential for a
large placebo effect in any study of tinnitus (Dobie 1999), and
so it is essential that any investigation of hearing aids for tinnitus
considers the potential impact of this effect.
Postulated mechanisms through which sound generators may be
beneficial for tinnitus include tinnitus masking by reducing au-
dibility (Vernon 1977) or by inducing a sense of relief (Vernon
2000), through habituation (Jastreboff 1993), by reversing abnor-
mal cortical reorganisation or activity thought to contribute to
tinnitus (Norena 2005; Tass 2012), or through the promotion of
relaxation (Sweetow 2010).
Combination hearing aids combine the above approaches within
one device (Tutaj 2018).
Potential modifiers of treatment outcome include the presence of
hearing loss, clinically significant anxiety or depression, or high
levels of tinnitus distress (which may be intractable to sound ther-
apy alone) (Hoare 2012;Hoare 2014a; Jastreboff 2004; Searchfield
2010; Searchfield 2017).
Why it is important to do this review
In England alone there are an estimated ¾ million GP con-
sultations every year where the primary complaint is tinnitus
(El-Shunnar 2011), equating to a major burden on healthcare ser-
vices. Hearing aids, sound generators and combination devices
(amplification aid sound generation within one device) are a com-
ponent of many tinnitus management programmes and together
with information and advice are a first line of management in
UK audiology departments for someone who has tinnitus (Hoare
2014; Hobson 2012; Sereda 2015; Tutaj 2018). These options are
also subject to ongoing research and development, for example to
examine the effectiveness of new technologies such as mobile ap-
plications, wireless streaming and alternative sound options such
as 3D sounds (Tutaj 2018).
Two previous Cochrane Reviews concluded that there was a
lack of evidence for the effectiveness of these management op-
tions (Hobson 2012; Hoare 2014). The first review looked at
sound therapy (masking) in the management of tinnitus in adults
(Hobson 2012). The methods and searches in that review are now
outdated, as is the use of term ’masking’ as the only suggested
mechanism of action for sound therapy. The second review looked
at amplification with hearing aids for patients with tinnitus and
co-existing hearing loss and an update of that review is now due
(Hoare 2014). The current review will provide an update to both
of these Cochrane Reviews and extend them to separately consider
the specific effects and safety of the three different sound therapy
options.
O B J E C T I V E S
To assess the effects of sound therapy (using amplification devices
and/or sound generators) for tinnitus in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with the following design characteristics:
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• randomised controlled trials, including cluster-randomised
(cross-over trials will be eligible if data from before the cross-over
are extractable, to avoid the potential for a carry-over
phenomenon).
We will exclude studies with the following design characteristics:
• quasi-randomised controlled studies.
We will apply no restrictions on language, year of publication or
publication status.
Types of participants
Adults (≥ 18 years) with acute or chronic subjective idiopathic
tinnitus.
Types of interventions
Amplification-only devices, sound generators and combination
devices (combined amplification and sound generation).
The comparators are amplification only, sound generator only and
combination device.
The main comparison pair(s) will be:
• amplification only versus waiting list control or placebo or
education/information only with no device;
• sound generator only versus waiting list control or placebo
or education/information only with no device;
• combination device versus waiting list control or placebo or
education/information only with no device.
Other possible comparison pairs include:
• amplification only versus sound generator only;
• combination device versus amplification only;
• combination device versus sound generator only.
Wewill exclude studies that have complex interventions, which ex-
plicitly include a sound therapy and other non-sound components
(e.g. psychotherapy) as a part of a programme (e.g. Neuromonics).
We will also exclude studies of neuromodulation (desynchronisa-
tion) devices (reviewed in Hoare 2015).
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Tinnitus symptom severity (such as the impact of tinnitus
on quality of life, activities of daily living and sleep), as measured
by the global score on a multi-item tinnitus questionnaire (Table
1). These include:
◦ Tinnitus Questionnaire (Hallam 1996; Hiller 1992);
◦ Tinnitus Functional Index (Meikle 2012);
◦ Tinnitus Handicap Inventory (Newman 1996);
◦ Tinnitus Handicap Questionnaire (Kuk 1990);
◦ Tinnitus Reaction Questionnaire (Wilson 1991);
◦ Tinnitus Severity Scale (Sweetow 1990).
We will update this list on an ongoing basis whenever other ques-
tionnaires are introduced.
• Significant adverse effect: increase in self-reported tinnitus
loudness.
Secondary outcomes
• Depressive symptoms or depression as measured by a
validated instrument, such as the Beck Depression Inventory
(Beck 1988; Beck 1996), the depression scale of the Hospital
Anxiety and Depression Scale (HADS; Zigmond 1983), and the
Hamilton Rating Scale for Depression (Hamilton 1960).
• Anxiety symptoms or generalised anxiety as measured by a
validated instrument, such as the anxiety scale of the Beck
Anxiety Inventory (Beck 1988), the anxiety scale of the HADS
(Zigmond 1983), or the Anxiety Sensitivity Index (Reiss 1986).
• Health-related quality of life as measured by a validated
instrument, such as the Short-Form 36 (Hays 1993),
WHOQOLBREF (Skevington 2004), other WHOQOL
versions or Health Utilities Index (Furlong 2001).
• Adverse effects associated with wearing the device such as
pain, discomfort, tenderness or skin irritation, or ear infections.
In addition, where possible we will report the newly developed
core outcomes for trials of sound therapy for tinnitus, these being
tinnitus intrusiveness, ability to ignore, concentration, quality
of sleep and sense of control (Fackrell 2017).
We will aim to measure long-term effects at three to six months.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct system-
atic searches for randomised controlled trials and controlled clin-
ical trials. There will be no language, publication year or publica-
tion status restrictions. We may contact original authors for clar-
ification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane ENT Register (search to date);
• the Cochrane Central Register of Controlled Trials
(CENTRAL, via the Cochrane Register of Studies (CRS) to
date);
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• Ovid MEDLINE(R) Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to date);
• Ovid Embase (1974 to date);
• Ovid PsycINFO (1806 to date);
• EBSCO CINAHL (1982 to date);
• Web of Knowledge, Web of Science (1945 to date);
• LILACS (Latin American and Caribbean Health Science
Information database; 1982 to date);
• ClinicalTrials.gov (search via the Cochrane Register of
Studies and www.clinicaltrials.gov to date);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (search to date).
The subject strategies for databases will be modelled on the search
strategies detailed in Appendix 1.Where appropriate, these will be
combined with subject strategy adaptations of the highly sensitive
search strategy designed by Cochrane for identifying randomised
controlled trials and controlled clinical trials (as described in the
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search Ovid MEDLINE to retrieve ex-
isting systematic reviews relevant to this systematic review, so that
we can scan their reference lists for additional trials. The Infor-
mation Specialist will also run non-systematic searches of Google
Scholar to retrieve grey literature and other sources of potential
trials.
We will not perform a separate search for adverse effects of sound
therapy (using amplification devices and/or sound generators) for
tinnitus. We will consider adverse effects described in the included
studies only.
Data collection and analysis
Selection of studies
Three authors (MS, AER and DAH) will independently review
all studies retrieved to determine their eligibility for inclusion in
the review. The authors will then review the full-text articles of the
retrieved studies and apply the inclusion criteria independently.
Any disagreements will be discussed between all three authors until
a consensus is reached.
Data extraction and management
MS, DJH, AER and JX will independently extract data using a
purposefully designed data extraction form. We will pilot the data
extraction form on a subset of articles and revise it as indicated
before formal data extraction begins. Where necessary or where
insufficient data are provided for the study, we will contact the
study authors for further information.
Information to be extracted will include: study design, setting,
methods or randomisation and blinding, power, inclusion and ex-
clusion criteria, type of intervention and control, treatment dura-
tion, treatment fidelity, type and duration of follow-up, and out-
come measures and statistical tests.
Data to be extracted will include: baseline characteristics of partic-
ipants (age, sex, duration of tinnitus, tinnitus symptom severity,
tinnitus loudness and pitch estimates, details of co-morbid hear-
ing loss, anxiety or depression), and details of any attrition or ex-
clusion.
Outcome data to be extracted will include: group mean and stan-
dard deviation at pre- and post-intervention and follow-up, and
results of any statistical tests of between-group comparisons.
We will also contact authors where further information is required
that is not contained within the study publication or in an accessi-
ble database. If not reported or provided by the authors we will es-
timate standard deviations in RevMan 5.3 (RevMan 2014) using
the available data, such as standard errors, confidence intervals, P
values and t values. Where data are only available in graph form,
the authors will make and agree numeric estimates.
After independent data extraction by MS, DJH, AER and JX,
all authors will review the extracted data for disagreements, and
revisit and discuss the relevant studies as required to reach a final
consensus.
Assessment of risk of bias in included studies
MS,DJH, AER and JXwill undertake assessment of the risk of bias
of the included trials independently, with the following taken into
consideration, as guided by theCochrane Handbook for Systematic
Reviews of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias. We
will resolve differences of opinion by discussion. If no consensus
is reached, we will consult the other authors.
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Measures of treatment effect
We will analyse dichotomous data as risk ratios (RR) with 95%
confidence intervals (CIs). We will summarise continuous out-
comes as mean difference (MD) with 95% CI. We will use stan-
dardised mean difference (SMD) (Cohen’s d effect size (ES)) when
different scales of measurement have been used to measure the
same outcome. A positive effect size indicates that the treatment
group achieved better outcomes than the control group.
Unit of analysis issues
For parallel-group RCTs the unit of analysis will be the group
mean. However, some studies included in the review may involve
clustering (for example, a group counselling intervention) or com-
pare more than two intervention groups. To avoid unit of analysis
errors we will consider alternative analyses for cluster-randomised
trials and for studies with more than two intervention groups. For
cluster-randomised trials we will adopt approximate analyses - ef-
fective sample sizes (Donner 2002). For studies with more than
two intervention groups, we will either combine groups to create
a single pair-wise comparison or, if this is not appropriate, select
the most relevant pair of interventions for comparison.
Dealing with missing data
Where necessary and where sufficient data from the study are not
provided, we will contact the authors of the study requesting fur-
ther details about missing data and reasons for the incompleteness
of the data. If no useful response is obtained, we will impute data
if we judge the data to be ’missing at random’. If we judge data to
be ’missing not at random’, the missing data may affect the overall
results; we will therefore not impute data. In the latter case, we
will conduct sensitivity analysis with different assumptions.
We will be alert to potential mislabelling or non-identification of
standard errors and standard deviations. Ourmethods for imputa-
tion will be according to chapter 7.7.3 of the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011).
If data are missing, we will use available case analysis using all data
(as reported) for all randomised patients available at the end of
the study/time point of interest, regardless of the actual treatment
received. We will consider the quality of outcome assessment as a
study limitation (GRADE) and not as a stratifying factor.
Assessment of heterogeneity
We will assess studies for clinical, statistical and methodological
heterogeneity. We will quantify statistical heterogeneity using the
I2 statistic and the Chi2 test. An approximate guide to interpre-
tation of the I2 statistic is provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011). An I2 value
of 50% or higher may represent substantial or considerable het-
erogeneity. Where Chi2 is greater than the degrees of freedom (K-
1 degrees of freedom, where K is the number of studies), then het-
erogeneity is likely to be present. We will consider heterogeneity
to be statistically significant if the P value is less than 0.10. We
will perform the meta-analysis using fixed-effect (in the absence
of heterogeneity) and random-effects modelling (in the presence
of heterogeneity). If the level of heterogeneity remains unclear we
will seek statistical advice.
Assessment of reporting biases
For each sound therapy intervention, we will investigate poten-
tial publication bias and the influence of individual studies on
the overall outcome identified in this review. We will search for
and request study protocols for the included studies and, where
available, we will evaluate whether there is evidence of selective
reporting. If a meta-analysis contains at least 10 studies, we will
assess publication bias using a funnel plot and Egger’s test.
Data synthesis
Wewill analyse separately the different sound therapy options (am-
plification only, sound generation only, combined amplification
and sound generation) and different durations of tinnitus (acute
and chronic). If more than one study is identified for a given op-
tion, and if combining studies is appropriate, we will use RevMan
5.3 to perform meta-analyses (RevMan 2014).
We will pool data from randomised controlled trials using a fixed-
effect model, except when heterogeneity is found. We will pool
dichotomous data using the RRmeasure.We will pool continuous
data using the SMDmeasure, if more than one instrument is used
to measure the same outcome.
We will consider the psychometric properties of outcome instru-
ments with regard to their suitability for pooling. For meta-analy-
ses on the primary outcome (tinnitus symptom severity), whenever
studies report outcomes measured by more than one instrument,
data will be included only when those instruments are known
to measure the same underlying construct of tinnitus symptom
severity (high convergent validity) and show a similar direction
of treatment-related effect. We will take the same approach for
secondary outcomes.
Network meta-analysis
Firstly, when studies are homogenous we will perform a head to
head pair-wise meta-analysis using a random-effects model using
STATA version 13 to estimate the absolute or relative measures
depending upon the outcome measure. For continuous data we
will use the SMD or Cohen’s d due to the various tools used for
measuring the same outcomes. For dichotomous outcomes we will
use risk ratios and 95% CI. We will perform network meta-analy-
sis within a frequentist framework using the mvmeta command in
STATA version 13 (Chaimani 2013). We will assume a common
heterogeneity variance across the different interventions. We will
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also evaluate the assumption of transitivity by looking at the dis-
tribution of the possible effect modifier and the baseline variables
of included studies in each network (Salanti 2009).
We will conduct a network plot to access the connection between
the interventions for each outcome. NMA combines direct and
indirect evidence for all relative treatment effects and can therefore
provide estimates with maximum power and increased precision (
Salanti 2008). InNMAwe assume any participants in the included
studies will have an equally likely chance to be randomised to
any of the treatment options. When studies follow the transitivity
assumption, we will conduct a multivariate random effect NMA
for each outcome.Wewill present the result of all comparisons in a
league table. To obtain the ranking probabilities of each treatment
we will use the surface under the cumulative ranking (SUCRA)
and the rankongram (Salanti 2011).
We will assess the agreement between direct and indirect evidence
measured as inconsistency employing the local and global method.
Wewill use the loop-specific approachmethod to evaluate the con-
sistency assumption in each closed loop to calculate the inconsis-
tency factor. Then, we will use the magnitude of the inconsistency
factors and their 95% CIs to infer the presence of inconsistency
in each loop (Salanti 2009). We will use the ’design-by-treatment’
model approach (Handbook 2011; Higgins 2012) to measure the
different sources of inconsistency in the entire network based on
the Chi2 test (Veroniki 2013).
Subgroup analysis and investigation of heterogeneity
If sufficient data are available, we will carry out subgroup analyses
to explore potential effectmodifiers. Thiswill be restricted to a very
small number of subgroups. The planned subgroups are defined
by:
• presence or absence of hearing loss (cut-off defined
according to pure tone average of 20 dB at 0.5, 1, 2 and 4 kHz);
• baseline tinnitus symptom severity (where the questionnaire
has a validated grading system to differentiate mild/moderate
and severe tinnitus);
• baseline anxiety or depression (presence or absence as
defined by the cut-off score on a validated questionnaire
measure).
Sensitivity analysis
We will conduct a sensitivity analysis by excluding those studies
with a high risk of bias, thereby checking the robustness of the
conclusion from the studies included in the meta-analysis. In ad-
dition, we will use sensitivity analyses for studies in which data
were imputed.
GRADE and ’Summary of findings’ table
Three independent authors (MS, DJH and JX) will use the
GRADE approach to rate the overall quality of evidence using
GRADEpro GDT ( https://gradepro.org/). The quality of evi-
dence reflects the extent to which we are confident that an estimate
of effect is correct and we will apply this in the interpretation of
results. There are four possible ratings: high, moderate, low and
very low. A rating of high quality of evidence implies that we are
confident in our estimate of effect and that further research is very
unlikely to change our confidence in the estimate of effect. A rat-
ing of very low quality implies that any estimate of effect obtained
is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
We will include a ’Summary of findings’ table, constructed accord-
ing to the recommendations described in the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011), for the
following comparison(s):
• Amplification only versus waiting list control, placebo,
education/information only with no device.
• Sound generator only versus waiting list control, placebo,
education/information only with no device.
• Combination devices versus waiting list control, placebo,
education/information only with no device, amplification only,
sound generator only.
We will include the following outcomes in the ’Summary of find-
ings’ table:
• tinnitus symptom severity;
• significant adverse effect (increase in self-reported tinnitus
loudness);
• depression;
• anxiety;
• health-related quality of life;
• adverse effects associated with wearing the device.
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A D D I T I O N A L T A B L E S
Table 1. Examples of questionnaires measuring tinnitus symptom severity
Measurement instrument (author, year) Number of items and subscales Internal consistency (Cronbach’s alpha for global
score)
Tinnitus Functional Index (Meikle 2012) 25 items, 8 subscales a = 0.97
Tinnitus Handicap Inventory (Newman
1996)
25 items, 3 subscales a = 0.93
Tinnitus Handicap Questionnaire (Kuk
1990)
27 items, 3 subscales a = 0.94
Tinnitus Questionnaire (Hallam 1996) 52 items, 5 subscales a = 0.94
Tinnitus Reaction Questionnaire (Wilson
1991)
26 items, 4 subscales a = 0.96
Tinnitus Severity Scale (Sweetow 1990) 15 items Not reported
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (CRS) MEDLINE (Ovid) Embase (Ovid)
1 MESH DESCRIPTOR Tinnitus EX-
PLODEALLANDCENTRAL:TARGET
2 (tinnit*):AB,EH,KW,KY,MC,MH,TI,
TO AND CENTRAL:TARGET 1
3 #1 OR #2 AND CENTRAL:TARGET
4 MESH DESCRIPTOR Hearing Aids
EXPLODE ALL AND CENTRAL:TAR-
GET
5 MESH DESCRIP-
TORPerceptualMasking EXPLODEALL
AND CENTRAL:TARGET
6 MESH DESCRIPTOR Acoustic Stimu-
lation EXPLODE ALL AND CENTRAL:
TARGET
7 MESH DESCRIPTOR Combined
1. exp Tinnitus/
2. tinnit*.ab,ti.
3. 1 or 2
4. exp Hearing Aids/
5. exp Perceptual Masking/
6. exp Acoustic Stimulation/
7. Combined Modality Therapy/
8. exp Music Therapy/
9. SOUND/th, tu [Therapy, Therapeutic
Use]
10. (((hearing or tinnitus) adj3 aid?) or ear-
mold? or (ear adj3 mold?)).ab,ti
11. (mask* or amplification).ab,ti.
12. (“therapeutic sound?” or “therapeutic
noise?” or “white noise?” or “tinnitus in-
1. exp tinnitus/
2. tinnit*.ab,ti.
3. 1 or 2
4. exp hearing aid/
5. exp auditory stimulation/
6. exp music therapy/
7. exp auditory masking/
8. (((hearing or tinnitus) adj3 aid?) or ear-
mold? or (ear adj3 mold?)).ab,ti
9. (mask* or amplification).ab,ti.
10. (“therapeutic sound?” or “therapeutic
noise?” or “white noise?” or “tinnitus in-
strument?” or “combination instrument?”
or “combination device?” or “static noise?”
or “tinnitus device?” or “relief product?” or
14Sound therapy (using amplification devices and/or sound generators) for tinnitus in adults (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Modality Therapy AND CENTRAL:
TARGET
8 MESH DESCRIPTOR Music Therapy
EXPLODE ALL AND CENTRAL:TAR-
GET
9 MESH DESCRIPTOR Sound WITH
QUALIFIER TU,TH AND CENTRAL:
TARGET
10 (((hearing or tinnitus) NEAR (aid or
aids)) or earmold* or (ear NEAR mold*)
):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET 657
11 (mask* or amplification):AB,EH,KW,
KY,MC,MH,TI,TO AND CENTRAL:
TARGET
12 (“therapeutic sound*” or “therapeu-
tic noise*” or “white noise*” or “tinni-
tus instrument*” or “combination instru-
ment*” or “combination device*” or “static
noise*” or “tinnitus device*” or “relief
product*” or “puretone device*” or “pure-
tone tinnitus” or “tinnitus system*”):AB,
EH,KW,KY,MC,MH,TI,TO ANDCEN-
TRAL:TARGET
13 (tinnitech* OR starkey* OR ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or
zen or danalogic or audimed or ipod):AB,
EH,KW,KY,MC,MH,TI,TO ANDCEN-
TRAL:TARGET
14 ((auditory or audio or acoustic or
noise* or sound* or music or audio) NEAR
(stimulat* or generator? or device? or fre-
quency or stimulus)):AB,EH,KW,KY,MC,
MH,TI,TO AND CENTRAL:TARGET
15 ((noise* or sound* or music) near
(therap* or training or treatment? or fre-
quency or intervention?)):AB,EH,KW,KY,
MC,MH,TI,TO AND CENTRAL:TAR-
GET
16 (tinnitus near pitch* near match*):AB,
EH,KW,KY,MC,MH,TI,TO ANDCEN-
TRAL:TARGET
17 #4 OR #5 OR #6 OR #7 OR #8 OR #
9 OR #10 OR #11 OR #12 OR #13 OR
#14 OR #15 OR #16 AND CENTRAL:
TARGET
18 #17 AND #3 AND CENTRAL:TAR-
strument?” or “combination instrument?”
or “combination device?” or “static noise?”
or “tinnitus device?” or “relief product?” or
“puretone device?” or “puretone tinnitus”
or “tinnitus system?”).ab,ti
13. (tinnitech* or starkey* or ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or zen
or danalogic or audimed or ipod).ab,ti
14. ((auditory or audio or acoustic or noise?
or sound? or music or audio) adj3 (stimu-
lat* or generator? or device? or frequency
or stimulus)).ab,ti
15. ((noise? or sound? or music) adj3
(therap*or training or treatment? or fre-
quency or intervention?)).ab,ti
16 (tinnitus adj3 pitch* adj3 match*).ab,ti.
17. or/4-16
18. 3 and 17
19. randomized controlled trial.pt.
20. controlled clinical trial.pt.
21. randomized.ab.
22. placebo.ab.
23. drug therapy.fs.
24. randomly.ab.
25. trial.ab.
26. groups.ab.
27. 18 or 19 or 20 or 21 or 22 or 23 or 24
or 25
28. exp animals/ not humans.sh.
29. 27 not 28
30. 18 and 98 491
“puretone device?” or “puretone tinnitus”
or “tinnitus system?”).ab,ti
11. (tinnitech* or starkey* or ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or zen
or danalogic or audimed or ipod).ab,ti
12. ((auditory or audio or acoustic or noise?
or sound? or music or audio) adj3 (stimu-
lat* or generator? or device? or frequency
or stimulus)).ab,ti
13. ((noise? or sound? or music) adj3
(therap*or training or treatment? or fre-
quency or intervention?)).ab,ti
14. (tinnitus adj3 pitch* adj3 match*).ab,
ti.
15. or/4-14
16. 3 and 15
17. (random* or factorial* or placebo* or
assign* or allocat* or crossover*).tw
18. (control* adj group*).tw.
19. (trial* and (control* or comparative)).
tw.
20. ((blind* ormask*) and (single or double
or triple or treble)).tw
21. (treatment adj arm*).tw.
22. (control* adj group*).tw.
23. (phase adj (III or three)).tw.
24. (versus or vs).tw.
25. rct.tw.
26. crossover procedure/
27. double blind procedure/
28. single blind procedure/
29. randomization/
30. placebo/
31. exp clinical trial/
32. parallel design/
33. Latin square design/
34. 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32 or 33
35. exp ANIMAL/ or expNONHUMAN/
or exp ANIMAL EXPERIMENT/ or exp
ANIMAL MODEL/
36. exp human/
37. 35 not 36
38. 34 not 37
39. 16 and 38 512
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